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Japanese 
Encephalitis 
Outbreak, 
Yuncheng, China, 
2006 
To the Editor: Japanese encepha-
litis (JE) epidemics have occurred only 
in Asia. More than 50,000 cases of JE 
with ≈10,000 deaths have been report-
ed since 1998 (1,2). The People’s Re-
public of China reported 5,104 cases 
and 214 deaths in 2005. Most of these 
deaths occurred in infants (3,4). 
During July and August 2006, 
an outbreak of viral encephalitis oc-
curred in Yuncheng, Shanxi Province, 
People’s Republic of China. A total of 
66 cases (1.32/100,000 population) 
were reported, including 19 deaths 
(case-fatality rate 28.8%). The cases 
had a widespread distribution over 9 
counties and involved 37 towns and 
61 administrative villages. The ratio 
of male-to-female patients was 1:0.89. 
A distinct clinical feature of this out-
break was the age distribution. More 
than 86% of the patients were >30 
years of age, with only 10% of pa-
tients <7 years of age; ≈95% of the 
deaths occurred in patients >50 years 
of age (5).
We report serologic and virologic 
ﬁ  ndings for the 2006 outbreak of viral 
encephalitis. Forty-six clinical speci-
mens collected from 34 patients who 
had a diagnosis of viral encephalitis, 
including 33 serum samples and 13 
cerebrospinal  ﬂ   uid (CSF) samples, 
were studied. All serum samples were 
screened for immunoglobulin M (IgM) 
to West Nile virus (WNV) by using the 
WNV IgM-capture ELISA kit (PanBio, 
Brisbane, Queensland, Australia) and 
for IgM to dengue virus or Japanese 
encephalitis virus (JEV) by using the 
JE-Dengue IgM Combination ELISA 
kit (PanBio). Results for JEV were con-
ﬁ  rmed by using the JE Virus IgM-Cap-
ture ELISA kit (Shanghai B & C Enter-
prise Development Co. Ltd, Shanghai, 
People’s Republic of China). 
WNV-speciﬁ   c or dengue vi-
rus–speciﬁ  c IgM was not detected in 
any samples. JEV-speciﬁ   c IgM was 
detected in 27 (80%) patients, which 
indicated recent JEV infections. The 
other 7 patients were negative for JEV 
by ELISA and reverse transcription–
PCR (RT-PCR). Increases >4-fold in 
neutralizing antibodies were detected 
in acute- and convalescent-phase se-
rum samples from 9 patients (10 se-
rum pairs were collected during the 
outbreak). 
Attempts were made to detect 
virus in CSF of patients and in 2,400 
mosquitoes. Mosquitoes (mainly Cu-
lex spp.) were collected in cow sheds 
and hog pens around houses and pro-
cessed into pools of 100. Total RNA 
was extracted from CSF or mosquito 
homogenate by using the QIAamp 
viral RNA extraction kit (QIAGEN, 
Valencia, CA, USA) according to the 
manufacturer’s speciﬁ  cations. RT was 
performed by using Ready-To-Go-You 
Prime First Strand Beads (Amersham 
Pharmacia Biotech, Piscatawy, NJ, 
USA) and a seminested PCR to ampli-
fy 492-bp gene fragments of the pre-
membrane (PrM) sequence of JEV by 
using the Takara LA Taq PCR kit (Ta-
kara Bio Inc., Shiga, Japan). The prim-
ers were derived from Ishikawa strain 
genome sequences (GenBank acces-
sion no. AB051292). Primers PrMF: 
5′-CGT TCT TCA AGT TTA CAG 
CAT TAG C-3′ (251–275), PrMR1: 
5′-CGY TTG GAA TGY CTR GTC 
CG-3′ (724–743), and PrMR2: 5′-
CCY RTG TTY CTG CCA AGC ATC 
CAM CC-3′ (901–925) were used. 
JEV PrM gene was ampliﬁ  ed from 
CSF of 6 (46%) of 13 patients and 10 
of 24 pools of mosquitoes by using the 
same seminested RT-PCR. To identify 
JEV genotype(s) involved in this out-
break, PCR products were sequenced. 
Eleven sequences (GenBank acces-
sion nos. EF434264–EF434274) were 
obtained from 6 patients and 5 pools 
of mosquitoes. The 11 sequences were 
compared phylogenetically with17 
known JEV strains of the 4 recognized 
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genotypes (classiﬁ  ed on the basis of 
a 240-nt region of the prM gene). As 
shown in the Figure, the 11 sequences 
were those of JEV.
Further analysis showed that these 
11 sequences can be grouped into gen-
otypes I and III. Both genotypes were 
found in patient and mosquito sam-
ples, indicating that these genotypes 
co-circulated during this JE outbreak.
JE has been endemic in Yuncheng 
for many years (6). A vaccine against 
JE (SA14–14–2) has been used in this 
area in infants, but not in adults. This 
might be 1 reason why a higher adult 
incidence was found in this outbreak. 
JEV genotype III had been the pre-
dominant genotype in previous years, 
but genotype I has been recently de-
tected at increased frequencies (7–10). 
Detection of 2 JEV genotypes in 1 epi-
demic has not been reported. Whether 
simultaneous circulation of >1 geno-
type during an outbreak indicates a 
new type of emergence of JEV or that 
this has occurred and not been detect-
ed is unknown.
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Figure. Phylogenetic analysis of Japanese encephalitis virus strains predicted from 
premembrane gene sequences. Neighbor-joining tree was generated by using MEGA 
3.1 software (www.megasoftware.net) and rooted with Murray Valley encephalitis (MVE) 
virus sequence information. Bootstrap conﬁ  dence limits for 1,000 replicates are indicated 
above each branch. Horizontal branch lengths are proportional to genetic distance; vertical 
branch lengths have no signiﬁ   cance. Scale bar indicates no. nucleotide substitutions 
per site. All sequences from this study are in boldface. Genotypes are indicated on the 
right. Designations are listed ﬁ  rst, followed by country, source, and year of isolation. CSF, 
cerebrospinal ﬂ  uid.LETTERS
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Chloroquine-
Resistant 
Plasmodium vivax, 
Brazilian Amazon
To the Editor: Plasmodium vivax 
is the protozoan that causes the second 
most common form of malaria. Some 
resistant strains to chloroquine (CQ) 
occur in a few places in Asia  and the 
Indo-Paciﬁ  c Region (1–4). Although 
resistance of P. vivax to CQ has al-
ready been described in South Ameri-
ca (5–7), there are limited data regard-
ing this issue.
CQ plus primaquine is the stan-
dard treatment for vivax malaria 
worldwide. Presently, this drug regi-
men exhibits satisfactory efﬁ  cacy in 
the Brazilian Amazon. However, in 
recent years several treatment fail-
ures presumably related to CQ resis-
tance, have been reported in the city 
of Manaus (Amazonas) where vivax 
malaria predominates (7). This obser-
vation warrants local attention despite 
these cases having no conﬁ  rmation 
of CQ blood levels  on the basis of 
the appearance of asexual parasites 
against CQ plus desethylchloroquine 
levels exceeding the minimally effec-
tive plasma concentration proposed for 
sensitive parasite strains (>10 ng/mL) 
(8), according to Pan American Health 
Organization recommendations (9).
From September 2004 to February 
2005, a 28-day in vivo test was con-
ducted at the Foundation for Tropical 
Medicine of Amazonas (FMTAM) in 
Manaus, Brazil, to assess the efﬁ  cacy 
of standard supervised CQ therapy. 
The test involved 166 volunteers with 
uncomplicated vivax malaria. Each 
volunteer was administered uncoated, 
scored, 150-mg CQ tablets (10 + 7.5 
+ 7.5 mg/kg at 24-hour intervals) (9). 
Primaquine was withheld until day 
28 (dose regimen of 30 mg/day for 7 
days). Among the 109 volunteers who 
completed the in vivo test, 19 had pos-
itive blood smears within the 28-day 
follow-up (1 on day 14, 3 on day 21, 
and 15 on day 28). All were required 
to undergo alternative therapy (meﬂ  o-
quine). Adequate CQ absorption was 
conﬁ  rmed in these cases on day 2 with 
a mean ± SD CQ plasma concentration 
of 785.4 ± 800.1 ng/mL) (10) Suspect-
ed therapeutic failure (P. vivax CQ re-
sistance) was conﬁ  rmed in 11 (10.1%) 
of 109 persons with a mean isolated 
choloroquine plasma concentration 
>10 ng/mL (356.6 ± 296.1 ng/mL) (9). 
Desethylchloroquine levels in plasma 
were not measured.
Previously, a CQ efﬁ  cacy study 
demonstrated that 4.4% of those test-
ed had CQ-resistant P. vivax ( 7). In 
comparison, the proportion of failures 
(10.1%) in the current study seems to 
be relevant; even though most of the 
P. vivax infections (98, 89.9%) were 
successfully evaluated and adequate 
clinical and parasitologic responses 
were obtained. Currently, the FMTAM 
Manaus Outpatient Clinic is detecting 
patients from different areas of the city 
who show parasitologic recurrences 
after correct treatment within 28 days 
of the routine clinical follow-up. This 
observation is an indirect indicator of 
the possible regional spread of P. vivax 
CQ-resistant strains (unpub. data).
We believe our ﬁ  ndings are im-
portant and merit the attention of 
local public health authorities. Con-
sidering the possibility of emerging 
underestimated  P. vivax CQ resis-
tance in Manaus, we feel it is essen-
tial to quickly clarify whether such 
documented resistance can copromote 
vivax malaria outbreaks in malaria-
endemic areas within the Amazon.
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